ASND (Ascendis Pharma AS) Marketable Securities: $0 Mil (As of Mar. 2026)


ASND Ascendis Pharma AS ASND
37 GF Score
Price $274.22
! 5 Warning Signs
View Full Analysis

What is Ascendis Pharma AS Marketable Securities?

Ascendis Pharma AS ASND +2.72% 37 Marketable Securities is $0 Mil as of Mar. 2026. GuruFocus rates ASND with a GF Score™ of 37/100. The stock has 5 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Ascendis Pharma AS's Marketable Securities for the quarter that ended in Mar. 2026 was $0 Mil.

Ascendis Pharma AS's annual Marketable Securities declined from Dec. 2023 ($8 Mil) to Dec. 2024 ($0 Mil) but then stayed the same from Dec. 2024 ($0 Mil) to Dec. 2025 ($0 Mil).

Ascendis Pharma AS  (NAS:ASND) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Ascendis Pharma AS Marketable Securities Related Terms

Ascendis Pharma AS Marketable Securities Historical Data

* Premium members only.

The historical data trend for Ascendis Pharma AS's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ascendis Pharma AS Marketable Securities Chart

Ascendis Pharma AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 266.44 307.93 7.93 0.00 0.00

Ascendis Pharma AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ASND
37GF Score
Ascendis Pharma AS ASND
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ascendis Pharma AS Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of $0 Mil mean?
Ascendis Pharma AS (ASND) has a Marketable Securities of $0 Mil as of Mar. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Ascendis Pharma AS and its competitors.
Is Ascendis Pharma AS's Marketable Securities too high?
Ascendis Pharma AS's current Marketable Securities is $0 Mil. Overall, Ascendis Pharma AS has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Ascendis Pharma AS's Marketable Securities compare to JAZZ and BBIO?
Ascendis Pharma AS's Marketable Securities of $0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Ascendis Pharma AS and its competitors. Ascendis Pharma AS's current Marketable Securities is $0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ascendis Pharma AS stock overvalued right now?
Ascendis Pharma AS (ASND) has a current Marketable Securities of $0 Mil. The current Marketable Securities is $0 Mil. Ascendis Pharma AS's overall GF Score™ is 37/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Ascendis Pharma AS (ASND), the current Marketable Securities is $0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Ascendis Pharma AS Business Description

Other Exchanges A1SN34:Brazil
Address Tuborg Boulevard 12, Hellerup, DNK, 2900
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology, which includes TransCon PTH, TransCon CNP, and others. It operates in the United States, Europe, and the rest of the world and derives the majority of its revenue from the United States.
37GF Score

Get the complete analysis for ASND

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$274.22
Price